27 - 29 May, 2026
Congress CenterBasel SwitzerlandDr. Chantal Hargreaves, PhDDirector, Drug Discovery at Nucleome TherapeuticsSpeaker
Profile
Chantal Hargreaves received her PhD from King’s College London, studying the role of somatic hypermutation in anti‑thyroid antibody generation. She completed postdoctoral research at the Universities of Southampton and Oxford, focusing on Fc gamma receptor genetics, cancer immunotherapy responses, and primary antibody deficiency. Chantal joined Nucleome Therapeutics in 2021 and is now Director in the Drug Discovery group.
Agenda Sessions
3D Genomics with Precision at Scale Has Solved the Challenge of Discovering Disease Targets from Human Genetics
, 10:50View Session